Objectives. To study the associations of adipokines with recovery from upper extremity soft tissue disorders (UESTDs) and to explore whether overweight or obesity modify these associations.
Introduction
Nearly one-third of the general population reports upper extremity pain during the preceding week [1] . Upper extremity pain is frequently caused by upper extremity soft tissue disorders (UESTDs). They are a common cause of work disability and may result in high health care costs. Of common UESTDs, the prevalence of rotator cuff tendinitis in the general population ranges between 4% and 9% [13] , epicondylitis between 1% and 3% [1, 3] and wrist tendinitis between 0.5% and 2% [1, 3] .
The aetiology of UESTDs seems to be multifactorial, involving both individual and occupational risk factors such as age, diabetes and physical workload as well as psychosocial factors [2, 4, 5] .
The effect of obesity on UESTDs is not well known. Few studies have reported an association between obesity and UESTDs [6, 7] , especially carpal tunnel syndrome [8] . Adipose tissue, in addition to energy storage, can act as an endocrine organ and release adipokines in response to metabolic signals. In obesity, the expression and release of leptin increases while those of adiponectin decrease. The circulating level of leptin, a food intakeregulating adipokine, is increased in some musculoskeletal disorders such as degenerative joint disorders. The level of leptin has been associated with the development of knee OA independently of BMI [9] . The role of adipokines in UESTDs is thus far unknown.
Our study population consisted of workers who have sought medical advice due to incipient UESTDs. Earlier results showed an association between the adipokine visfatin and intensity of upper extremity pain at baseline [10] . The aim of this prospective study was to determine whether adipokines-particularly visfatin-predict recovery from UESTDs. Moreover, we explored whether the relationship between serum adipokines and recovery from UESTDs is modified by overweight or obesity.
Methods

Patients
In this follow-up study, patients seeking medical advice due to incipient upper extremity symptoms with symptom duration <1 month were referred for consultation to the Finnish Institute of Occupational Health from spring 2006 to fall 2008. We included all actively working subjects meeting diagnostic criteria based on physical examination. Conditions included shoulder disorders (e.g. rotator cuff tendinitis), elbow disorders (e.g. humeral epicondylitis) and wrist disorders (e.g. tenosynovitis), as well as non-specific disorders.
We excluded patients whose main problem was a spine or cervical disorder, advanced OA, autoimmune disease, FM, malignancy, history of recent injury, former surgery related to the current problem or the presence of deformity. Aiming to eliminate chronic problems or potential traumas, we also excluded subjects with work absence of 52 weeks prior to the medical examination, those needing sick leave immediately after the examination and those with three or more pain episodes of the same disorder during the past year. This study was approved by the Helsinki University Hospital district ethics committee on 15 August 2005. All the participants signed an informed consent form.
Outcome
The outcome of this study was full or substantial recovery from UESTDs, assessed by phone interviews. UESTD symptoms were determined during the primary visit by the examining physician with a standardized questionnaire and clinical test procedure. Subsequently, trained nurses inquired about the recovery of the participants by phone at 2, 8 and 12 weeks. The interviewer asked whether compared with the previous enquiry the disorder had fully recovered, recovered substantially, remained unchanged or been exacerbated. We dichotomized the outcome, classifying recovered fully or substantially versus remained unchanged or exacerbated.
Independent variables
At baseline we measured body height and weight with standard procedures. The subjects were categorized according to BMI into underweight (BMI < 18.5), normal weight (BMI 18.524.9), overweight (BMI 25.029.9) and obese (BMI 5 30.0).
Smoking was classified as never, former, occasional or current. Alcohol consumption was determined as the frequency of drinking alcohol per time unit, categorized into two groups: <2 times/week or 52 times/week. Physical exercise was defined as the number of sessions per week of physical activity for at least 30 min causing sweating or shortness of breath and categorized into none or occasionally, 12 times/week or 53 times per week.
Each patient's exposure to physical load factors was assessed with a standardized form inquiring about the frequency of heavy lifting, duration of working with the hand above shoulder level, prolonged forceful gripping, pinch grip that either required exertion or deviated wrist posture and the use of vibrating tools. Exposure to each physical load factor was defined as being exposed for 510% of the work time during a workday.
Job strain was evaluated using the 14-item Job Content Questionnaire (5 for job demands and 9 for job control), each item being assessed with a 5-point scale ranging from strongly agree to strongly disagree. We dichotomized job demand and job control at the median to generate a job strain variable, with high demand and low control signifying high job strain.
Fear avoidance beliefs were assessed by using four items adapted from Waddell et al. [11] . The sum variable was dichotomized defining scores 518 out of 24 as elevated.
The nine-item Patient Health Questionnaire (PHQ-9) was used to assess depressive symptoms with a 4-point scale (03), with the total score ranging from 0 to 27. We defined mild to severe depressive symptoms according to the recommended cut-off value of 55. Sleep disturbance was defined as waking during the night or in the early hours, classified into never or now and then vs often or always.
Fasting serum samples were collected and stored at À20 C. Serum adipokines were determined using ELISA kits according to the manufacturer's instructions [leptin, adiponectin, resistin (DuoSet ELISA, R&D Systems, Minneapolis, MN, USA) and visfatin (Human Visfatin ELISA kit, AdipoGen, San Diego, CA, USA).
Statistical analysis
To study the associations between adipokines and recovery we used the generalized estimating equation (GEE) with an exchangeable correlation structure to analyse repeated measures data. We used a robust variance estimator to compute standard errors. In GEE we included age, gender, follow-up time, physical activity, alcohol consumption, smoking, BMI, sleep disturbance and job strain as covariates in the final models. Each of the adipokines was studied separately in the above models. We performed subgroup analyses for tendon disorders and upper limb non-specific pain. Moreover, we assessed with stratified analysis whether the relationship between serum adipokines and recovery from UESTDs is modified by overweight/obesity. We used Stata version 10 software (StataCorp, College Station, TX, USA) for the analysis.
Results
Background characteristics
A total of 163 UESTD patients (141 females and 22 males) with a mean age of 45 years was included. The response www.rheumatology.oxfordjournals.org
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Adipokines in upper extremity soft tissue disorders rate to the follow-up questionnaire was 87.7% at 2 weeks, 86.5% at 8 weeks and 84.0% at 12 weeks. Of the participants, 30% were overweight, 14% obese and 20% were occasional or current smokers. Thirty-seven per cent were exposed to physical workload factors, 26% reported high job strain and 29% reported sleep disturbance. Overall, 27.5% reported full or substantial recovery after 8 weeks of follow-up and 32% after 12 weeks.
Factors associated with recovery from UESTDs
Older patients and those who were overweight or obese tended to report lower recovery from UESTDs during the follow-up than younger or non-overweight patients ( Table 1) . On the other hand, those consuming alcohol at least twice per week tended to have a higher recovery rate. BMI was correlated with the level of leptin [Pearson's correlation coefficient (r) = 0.624]. It showed a weaker correlation with adiponectin (r = À0.184) and visfatin (r = 0.159) and was not correlated with resistin (r = À0.036). The four adipokines were not correlated with each other (range of r between À0.014 and 0.133).
Higher levels of resistin at baseline predicted a higher recovery rate after 8 weeks of follow-up [odds ratio (OR) = 1.58, 95% CI 1.18, 2.11 for a 1 S.D. increase]. Moreover, higher levels of visfatin showed a similar tendency (OR = 1.29, 95% CI 0.94, 1.78 for a 1 S.D. increase). On the other hand, higher levels of leptin showed a tendency to predict a lower rate of recovery (OR = 0.73, 95% CI 0.51, 1.02 for a 1 S.D. increase). The association between resistin and recovery remained statistically significant after adjustment for age, gender, follow-up time, physical activity, alcohol consumption, smoking, BMI, sleep disturbance and job strain (OR = 1.53, 95% CI 1.15, 2.04). None of the four adipokines was associated with recovery at 12 weeks.
In subgroup analyses, higher levels of resistin and visfatin at baseline predicted recovery after 8 weeks of follow-up in non-overweight patients and not in overweight or obese patients (Table 2) . Moreover, higher levels of resistin were associated with a higher recovery rate in both tendon disorders and non-specific upper extremity pain, whereas higher levels of visfatin were associated with a higher recovery rate only in those with a tendon disorder and not in those with non-specific upper extremity pain.
Discussion
This prospective study used a patient population with incipient UESTD to study the role of adipokines in recovery. The results showed that higher levels of resistin and visfatin may predict higher recovery rates, whereas higher levels of leptin may predict lower recovery rates from UESTDs. The associations between adipokines and recovery were seen up to 8 weeks, but not thereafter.
The acute and subacute inflammatory phase of UESTDs has been reported to last from 6 to 12 weeks. Since only those with symptom duration of <30 days were included, the 8-week follow-up falls within 12 weeks of symptom onset, i.e. within the acute or subacute stage. The adipokines resistin and visfatin may have anti-inflammatory effects during the acute or subacute stage of UESTDs.
The sources of resistin and visfatin are not well known [12] . Resistin may originate from inflammatory cells of fat tissue. It seems that inflammation stimulates the release of resistin and visfatin [12] . They are both regarded as important pro-inflammatory mediators and their secretion is up-regulated during inflammation [13] . It seems that both resistin [14] and visfatin [15] are involved in the pathogenesis of inflammatory degenerative joint disorders. Resistin increases the release of numerous pro-inflammatory cytokines such as TNF-a and IL-12 from macrophages and monocytes [12, 13] . The role of resistin in inflammation is to increase leucocyte infiltration into tissues [12] . Moreover, resistin affects only innate immunity. In that sense, resistin differs from leptin, for example, which is largely expressed by fat tissue, showing both innate and adaptive immunity functions. Both resistin and visfatin might have a bidirectional function and also stimulate anti-inflammatory responses by activating TGF-b [16] , a cytokine also recognized in UESTDs [17] . TGF-b modulates, for instance, T lymphocytes and participates in tissue fibrogenic remodelling. In UESTDs, TGF-b cooperates at various tendon healing stages [18] . Accordingly, TGF-b establishes a potential link between resistin and visfatin and UESTD recovery. Resistin may also participate in the processes of calcification [19] , suggesting a possible association with calcium deposit accumulation in, for example, rotator cuff tendinopathy.
Our results suggest a poorer recovery from UESTDs for those with higher levels of leptin. In line with previous reports, leptin was correlated with BMI. As a proinflammatory protein, leptin is able to modify inflammatory disorders such as asthma and chronic colitis by counteracting the effect of TGF-b [20] . Our results showed an association between resistin and visfatin and recovery from UESTDs in subjects with normal weight, but not in overweight or obese subjects. Consequently leptin may prevent recovery from UESTDs by antagonizing resistin and visfatin by blocking the effects of TGF-b.
We had repeated observations on individuals over time. We used the GEE and reported ORs but not relative risks.
In this study, since recovery from UESTDs was common, the ORs overestimated the relative risks. Moreover, a clinical examination has limitations in defining UESTDs.
To conclude, the adipokines resistin and visfatin may predict UESTD recovery and this effect could be related to their role in stimulating anti-inflammatory response mechanisms. Higher levels of leptin may prevent recovery from UESTDs. The findings present new UESTD mechanisms that should be looked at in larger-scale longitudinal studies.
Rheumatology key messages
. Higher levels of adipokines resistin and visfatin predicted greater recovery from upper extremity soft tissue disorders. . Higher levels of adipokine leptin predicted lower recovery from upper extremity soft tissue disorders. . Overweight/obesity modified the effects of resistin and visfatin on recovery from upper extremity soft tissue disorders. 
